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Abstract 
 
Sprint intensity interval training (SIT) is reported to improve blood glucose control and may 
be a useful public health tool. The sirtuins and associated genes are emerging as key players in 
blood glucose control. This study investigated the interplay between the sirtuin/NAD system 
and individual variation in insulin sensitivity responses after SIT in young healthy individuals. 
Before and after 4 weeks of SIT body mass and fat percentage were measured and oral glucose 
tolerance tests (OGTT) performed in 20 young healthy participants (7 females). Blood gene 
expression profiles (all 7 mammalian sirtuin genes and 15 enzymes involved in conversion of 
tryptophan, bioavailable vitamin B3 and metabolic precursors to NAD). NAD/NADP was 
measured in whole blood. Significant reductions in body weight and body fat post-SIT were 
associated with altered lipid profiles, NAD/NADP and regulation of components of the 
sirtuin/NAD system (NAMPT, NMNAT1, CD38 and ABCA1). Variable improvements in 
measured metabolic health parameters were evident and attributed to different responses in 
males and females, together with marked inter-individual variation in responses of the 
sirtuin/NAD system to SIT.  
 
Keywords: insulin sensitivity, interval exercise, body composition, sirtuin system, inter-
individual variation, GeXP 
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Introduction 
 
Insulin resistance (IR) is a major risk factor for the development of type 2 diabetes (T2D) and 
people with IR and/or T2D have been found to have 2-4 fold greater risk of CVD with 80% of 
people with T2D dying from CVD (Capewell  et al. 2009). T2D prevalence is rising, with ~400 
million global cases (projected to rise to ~600 million cases by 2035), it accounts for >10% of 
healthcare spending (International Diabetes Federation, 2013). Lack of physical activity and 
excess weight are the main factors thought to be responsible for this high, and increasing, 
prevalence. For this reason, and to achieve many of the other health benefits, people are 
recommended to participate in 150 minutes of moderate or 75 minutes of vigorous intensity 
exercise per week. 
 
Indeed, moderate intensity exercise (150 min/week) has been shown to be effective in reducing 
T2D to a greater extent than treatment with metformin (Knowler et al. 2002). Sprint interval 
training (SIT) has emerged as a strategy that can improve exercise performance, glucose 
control, insulin sensitivity, mitochondrial capacity, endothelial function and reduce 
postprandial triacylglycerol in healthy individuals after as little as 2 weeks (Babraj et al. 2009; 
Burgomaster et al. 2005; Gabriel et al. 2012; Little et al. 2010; Tjønna et al. 2008). A wealth 
of evidence demonstrates the health benefits of SIT, but inter-individual variation in responses 
implies interactions with genetics (Timmons et al. 2010) and requires investigation to optimise 
SIT interventions. 
 
SIRTUIN1 and the enzymes crucial in generating the sirtuin cofactor, nicotinamide adenine 
dinucleotide (NAD), have recently been implicated in diet and age-induced pathogenesis of 
T2D (Dong 2012; Haigis and Sinclair 2010; Huynh  et al. 2013). The sirtuin/NAD system is 
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also responsive to altered glucose regulation during the development of diet induced obesity 
(Drew et al 2016). Increased physical activity is associated with beneficial effects on metabolic 
health that are associated with altered regulation of the sirtuin system (Koltai et al. 2010). 
Further research is necessary to decipher the components of the sirtuin system that respond to 
exercise interventions that improve metabolic health. The sirtuin/NAD system is compromised 
by interactions with individual genetics (Kilic et al. 2014) since all seven sirtuins (SIRT1-7) 
and NAD biosynthesis enzymes are subject to genetic variation. Sirtuins are dependent on an 
adequate supply of NAD cofactors for enzymatic activity to regulate cellular processes linking 
them to the energy status of cells via cellular generation of nicotinamide. NAD generation is 
dependent on dietary intake of tryptophan and bioavailable niacin, but importantly NAD can 
be regenerated, independent of diet, by activation of salvage pathways that are upregulated in 
response to exercise (Hubbard and Sinclair 2014).  
 
Recent technological advances present opportunities to predict health status and benefits 
conferred by lifestyle interventions using gene expression profiling of whole blood (Drew et al 
2012). Considering the difficulties in accessing target tissues in human subjects this presents a 
strategy warranting consideration for research to identify individual responses to diet and 
lifestyle interventions. Consequently, our lab has been conducting studies to determine the 
feasibility of whole blood gene expression profiling to identify responses to interventions in 
humans (Drew et al 2014). This led to identification of variable levels of SIRT1 in human whole 
blood from apparently healthy individuals (Drew et al. 2014, Andraos et al 2016). Further 
investigation revealed that individuals with low SIRT1 exhibited higher levels of plasma 
inflammatory markers (TNFα), deregulated metabolic responses to food consumption (absence 
of a postprandial SOCS3 response), elevated p53 and low levels of high density lipoprotein 
cholesterol (HDL), factors indicative of reduced health status and metabolic stress (Drew et al. 
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2014, Andraos et al 2016). Importantly, these studies have demonstrated stable whole blood 
gene expression profiles that characterise individual subjects and their individual responses to 
dietary intervention.  
 
Thus the aim of this study was to determine changes in anthropometric and metabolic measures 
in response to SIT. Secondly, the study aimed to determine whether these changes were 
associated with modulation of the sirtuin/NAD system using human whole blood gene 
expression profiling. We hypothesised that improvements in outcome measures following SIT 
would be associated with specific changes in components of the sirutin/NAD system.  
 
Materials and Methods 
 
Study population  
 
Twenty recreationally active, but not specifically trained (not engaged in physical training to 
increase strength, aerobic fitness, speed, fitness or skillful practice for a specific sport or 
activity), participants aged 18-35 years, non-smokers, free of cardiovascular, metabolic or 
haematological disorders were recruited. The study was approved by the University of 
Aberdeen College Ethical Review Board. All participants were fully informed of the aims, risks 
and discomfort associated with the investigation before providing written informed consent. 
 
Pre-Experimental and Post Training Procedures 
 
Participants were asked to complete a 4 day estimated food diary (2 weekdays and 2 weekend 
days, on 4 consecutive days) directly preceding the SIT intervention. Recorded food diary data 
7 
 
was input into NetWISP dietary software analysis and patterns of daily food and nutrient intake 
were then determined, with specific reference to macronutrients and micronutrients associated 
with NAD generation (e.g. niacin). Participants were asked to maintain their habitual dietary 
intake and physical activity patterns for the duration of the study.  
 
Participants attended the laboratory in the morning after an overnight fast (from 10pm the 
previous evening) having abstained from strenuous exercise, caffeine and alcohol for 24h. 
Blood samples and the measurements detailed below were obtained no more than 1 week prior 
to the SIT intervention and 2 days after the final training session. Body mass and height were 
measured using standard scales and stadiometers. Subcutaneous body fat was measured at four 
points on the body (biceps, triceps, suprailiac and subscapular) to the nearest 0.2mm using 
skinfold callipers (Harpenden) and converted to body fat percentage using the equations of 
(Durnin and Womersley  1974). Waist/hip ratio was assessed using a tape to measure hip and 
waist circumferences to the nearest 1cm. An oral glucose tolerance test (OGTT) was 
performed. Baseline venous blood samples were collected (K3 EDTA and Na Heparin 
Vacuettes, Greiner Bio-One and Paxgene RNA tube, PreAnalytiX) before ingestion of a 75g 
glucose bolus (436ml Lucozade Original). Venous blood samples were then collected at 60, 90 
and 120 min after the consumption of the 75g glucose bolus. Whole blood collected in Na 
Heparin tubes were snap frozen prior to NAD assay (see below). Plasma was prepared by 
centrifugation (Eppendorf Centrifuge 5702/R) at 4000rpm, 4°C for 10 minutes, aliquoted and 
stored -20°C. Glucose and insulin concentrations were then measured using commercially 
available assays (see below). Blood collected in the Paxgene tubes was stored according to the 
manufacturer’s instructions prior to total RNA extraction (see below).  
 
Exercise Training 
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The SIT program was performed using a cycle ergometer and involved 3 sessions per week for 
4 weeks. The participants warmed up for 3 mins at a workload of 50 Watts, followed by 4-6 
(building from 4 to 6 over the first 6 sessions) maximal 30s sprints at a resistance equivalent to 
7.5% of body mass with 3 minutes unloaded cycling between sets. This was followed by a 3 
min cool down at 50 Watts. Participants were instructed to perform each sprint maximally with 
encouragement given during each sprint. The intensity of each bout was not recorded. Once 
carrying out 6 sprints each session lasted 24 mins. Participants performed this protocol three 
times each week for a 4-week period and all sessions were supervised.  
 
Glucose and Insulin Analysis  
 
Glucose (Human Glucose, Randox, UK) and insulin (Human Insulin, Mercodia UK) were 
assayed in plasma using commercially available kits according to the manufacturer’s 
instructions and spectrophotometers, a Camspec M330B and a Biotek, Synergy HT multi-mode 
microplate reader respectively.  
 
The AUC for both glucose and insulin concentrations during the OGTT were calculated using 
the trapezoid rule. Insulin sensitivity was estimated using the Cederholm index (Equation 1): 
 
Equation 1: ISICederholm = 75000 + (G0 – G120) x 180 x 0.19 x BW/120 X GMean x log (IMean) 
 
Where BW = body weight, G0 and G120 = plasma glucose concentration at 0 and 120 minutes 
(mmol.l-1) respectively, and IMean and GMean = mean insulin (mU.l
-1) and glucose (mmol.l-1) 
concentrations during the OGTT respectively. 
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Lipid profiling  
 
Lipid profiles (total cholesterol, HDL, LDL, triglycerides, Non-HDL and LDL: HDL ratio) of 
baseline (pre and post SIT) were measured from whole blood samples using commercially 
available kits (Alere Cholestech LDX® Lipid Profile Cassettes), in accordance with 
manufacturer’s instructions. 
 
Blood expression profiling of sirtuin and NAD biosynthetic enzyme genes  
 
Total RNA was extracted from human whole blood samples collected at baseline (pre and post 
SIT) and 60 min post OGTT in PAXgene® blood RNA tubes (PreAnalytiX GmbH) (2.5ml) 
using a PAXgene Blood RNA Kit (Qiagen, Crawley, UK), incorporating DNase digestion. 
RNA quality was assessed using a NanoDrop Spectrophotometer (NanoDrop Technologies, 
LabTech International, UK) and the Agilent Bioanalyser (Agilent Technologies, Bracknell, 
UK). Whole blood total RNA (50 ng) was assayed for sirtuin and NAD biosynthetic enzyme 
gene targets using the GenomeLab™ GeXP Genetic Analysis System (Beckman Coulter) and 
our in-house custom designed assay, the hSIRTNADPlex. The hSIRTNADPlex incorporates 
25 gene targets, including all 7 mammalian sirtuin genes (SIRT1-7), 15 enzymes involved in 
conversion of tryptophan, niacin, the novel vitamin, nicotinamide riboside, and metabolic 
precursors to NAD, together with 3 reference genes and a synthetic reference messenger RNA 
transcript for measuring relative quantitation of gene expression and reaction efficiencies 
respectively (Supplementary File S1). Details of the the GenomeLab System for design of in-
house custom designed multiplex assays and application to conduct blood gene expression 
profiling have been published previously (Drew et al. 2011; Drew et al. 2014) and are described 
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in Supplementary File S2. Fragment analysis of the generated hSIRTNADPlex PCR products 
was conducted using the Beckman Coulter CEQ 8000 GeXP Genetic Analysis system. The raw 
data generated using the GenomeLab™ GeXP Series Software Suite v11.0 was then exported 
using the GeXP Fragment Analysis Module and normalized using the GeXP Data Tool. 
 
NAD and NADP assay  
 
NAD and NADP were assessed in whole blood (50ul) at baseline (pre and post SIT) using 
methods described by Jacobsen and Jacobsen (1997) with modifications as described by Creeke 
et al. 2007). Spectrophotometric readings were assayed using an MRX plate reader (Dynatech 
Laboratories). 
 
Bradford Assay 
 
Commercially available reagents (Bradford Reagent, PBS, BSA; Sigma-Aldrich® UK) and 96-
well microtiter plates (F96 Maxisorp NUNC immunoplate, VWR) were used to determine total 
protein content of plasma samples pre and post SIT intervention using standard Bradford assay 
procedure. Absorbance was measured using a standard curve and plate reader (MRX plate 
reader, Dynatech Laboratories) at 595nm. 
 
NAMPT and Vitamin B3  
 
Vitamin B3 and NAMPT concentrations were determined via commercially available enzyme-
linked immunosorbent assay (ELISA) kits (RayBio® and MyBioSource®, USA) according to 
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the manufacturer’s instructions. NAMPT concentrations were subsequently standardised 
against total protein content assessed by Bradford assay.  
 
Statistics 
 
Plasma glucose and insulin responses to the pre-training and post-training OGTTs were 
analysed using two-way repeated measures ANOVA with post hoc t-tests. Paired t-tests were 
used to assess significant changes in anthropometric measures, metabolic biomarkers, gene 
expression and other relevant markers from pre to post SIT intervention (p<0.05). Principal 
Component Analysis (PCA) and Partial Least Squares (PLS) analyses were performed using 
SIMCA-P+ 12.0 software (MKS Instruments UK Ltd, Cheshire). PCA was conducted with 
normalised gene expression and PLS was performed using normalised gene expression data 
(Y) and anthropometric and metabolic marker data (X). Pearson correlations were calculated 
using SPSS. 
 
Results 
 
Study participants 
 
Twenty individuals were recruited to participate in the study (13 males and 7 females) and all 
completed (100% attendance at sessions) the 4 week supervised SIT intervention. The mean 
±SD age was 22.8 ±2.8 years, height was 1.77±0.11 m and weight was 73.6±14.3 kg. 
 
Food diaries 
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Estimated daily macronutrient and niacin intakes were calculated from 14 of the 20 participants 
(7 female) that returned completed food diaries (Table 1). The data collected indicated mean 
macronutrient intakes within the normal range recommended intakes prior to study 
participation. The % of total daily energy ± SEM intakes were fat 33.6 ± 2.3, protein 17.8 ± 
0.9 and carbohydrate 44.5 ± 2.5. Individual niacin intake was varied, with mean niacin intake 
27.8 ± 3.1 mg/day, ranging from 14.84 – 60.34 mg/day. Participants were asked to maintain 
their habitual dietary intake patterns for the duration of the SIT intervention.  
 
Anthropometric data 
 
Anthropometric measurements (n=20) pre and post SIT are shown (Table 2). Significant 
reductions in body mass (p=0.023) and body fat percentage (p=0.0004) were seen after SIT 
(Table 2). No significant differences were observed in BMI (p=0.07) or waist:hip ratio (p=0.19) 
post SIT (Table 2). However, review of individual responses to SIT indicated that there was 
inter-individual variation, with some, but not all participants responding favourably (Figures 
1A-D).  
 
Glucose, insulin and insulin sensitivity 
 
Mean glucose, insulin (Table 3) and glucose concentrations following OGTT (Figure 2A) were 
not significantly altered in response to SIT. Glucose area under the curve (AUC) did not 
significantly change post SIT (p=0.34). Mean glucose AUC change post SIT was -15.8 ± 
72.9mmol.L-1. However, inter-individual changes were observed (range, -162.9mmol.L-1 to 
+153.2mmol.L-1) in glucose AUC with 13 participants showing a reduction (Figure 2B). Mean 
insulin AUC was also not significantly reduced (p=0.38) post SIT (Figure 2C).  However, 
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despite the lack of significant decreases, mean insulin AUC change was -194.5 ± 971.3mU.L-
1, with 14 participants having reduced insulin AUC post SIT (range: -1679mU.L-1 to 
+2302mU.L-1) (Figure 2D). The mean insulin sensitivity increase following 4 weeks SIT was 
2.62 ± 13.6mg.mUl-1.min, but this was not significant (p=0.40) (Figure 2E). It was noted that 
12 of the 20 participants had increased insulin sensitivity post SIT (range: +25.7mg.mUl-1.min 
to -23mg.mUl-1.min) (Figure 2F). 
 
Lipid profiling 
 
Lipid profiles, total cholesterol (p=0.42), HDL (p=0.95), LDL (p=0.23), triglycerides (p=0.30), 
non HDL (0.44) and LDL: HDL ratios (p=0.63) were not significantly altered in response to 
SIT (n=19) (Table 3) and a wide range of responses observed (data not shown). 
 
Transcriptional responses of SIRT/NAD system to SIT  
 
The hSIRTNADPlex gene expression profiles measured in whole blood total RNA (RIN values 
7.0-9.3) pre and post SIT and post OGTT normalised to UBE2D2, established as a stably 
expressed transcript in blood using geNORM (Pattyn et al. 2003), are shown (Figure 3). Small, 
but significant changes in response to SIT and OGTT were observed (Figure 3). The most 
prominent responses were up regulation of ABCA1 (0.11 + 0.04 p < 0.05) and NAMPT (0.16 
+ 0.07 p < 0.05) post SIT and glucose pre and post SIT. The up regulation of ABCA1 (p < 
0.05) in response to glucose was significantly increased post SIT (Figure 3). NMNAT1 was 
also up-regulated significantly in response to glucose both pre and post SIT (Figure 3). While 
SIRT5 and CD38 were down-regulated in response to glucose both pre and post SIT (Figure 
3). In addition, HIC1 (p < 0.05), SIRT4 (p < 0.05), NMRK1 (p < 0.05), PSMB6 (p < 0.05), 
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PARP1 (p < 0.05), SIRT2 (p < 0.05), SIRT3 (p < 0.05) and SIRT7 (p < 0.01) showed 
significantly differing responses to OGTT pre and post SIT. Inter-individual variation in gene 
expression was observed in the genes that were shown to be significantly regulated in response 
to SIT.  
 
Vitamin B3 concentrations 
 
Decreased mean plasma vitamin B3 concentrations following SIT and in response to the OGTT 
were not significant (Figure 4A) with a wide range of responses observed pre to post SIT levels 
(range: -1.22μmol.L-1 to +0.59μmol.L-1). Thirteen of the 20 participants had reduced levels of 
vitamin B3 post SIT (Figure 4B).  
 
NAD: NADP ratio analysis 
 
Whole blood (n=11) NAD (p=0.91, mean decrease 1.6 ± 50nmol.L-1) and NADP (p=0.07, 
mean increase of 21.8 ± 36.3nmol.L-1) levels did not significantly change post SIT. The NAD: 
NADP ratio was significantly reduced after 4 weeks of SIT (p=0.014) compared with baseline 
measures (Figure 4C), with a mean decrease of 0.34 ± 0.47 (range: -0.37 to +0.04) (Figure 4D).  
 
NAMPT concentration 
 
NAMPT concentrations did not change significantly post SIT at 0 (p=0.97), 60 (p=0.19) and 
120 (p=0.84) minute time points (Figure 4E). Inter-individual variation in NAMPT plasma 
concentrations were observed ranging from +0.051ng/mg and -0.043ng/mg (Figure 4F). 
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Correlated SIRT/NAD gene expression and metabolic markers 
 
Expression of NAMPT, CD38, ABCA1 and NMNAT1 were all positively correlated following 
SIT, while pre SIT expression was not (Table 4). Correlations indicated post SIT NAMPT was 
positively associated with post SIT ABCA1 (r=0.696, p=0.001) and NMNAT1 (r=0.660, 
p=0.002). Additionally, post SIT ABCA1 was positively associated with post SIT CD38 
(r=0.615, p=0.004) and NMNAT1 (r=0.689, p=0.001). Post SIT measures of NMNAT1 
demonstrated positive relationships with post SIT measures of CD38 (r=0.459, p=0.042) and 
ABCA1 (r=0.689, p=0.001).  
 
Potential co-regulated expression of NAMPT, CD38, ABCA1 and NMNAT1 was further 
investigated by determining correlations with metabolic markers pre and post SIT. Notably, 
plasma glucose and cholesterols were associated with NAMPT and ABCA1 regulation. NAMPT 
and ABCA1 were positively correlated with post SIT, but not pre SIT fasted glucose (NAMPT 
r = 0.636, p = 0.003; ABCA1, r = 0.466, p = 0.038) (Table 5).  NAMPT and glucose AUC (r = 
0.462, p = 0.04) were also positively correlated post SIT, but not pre SIT (Table 5). NAMPT 
was negatively correlated with LDL (r = -0.497, p = 0.03) (Table 5). NAMPT expression was 
also negatively associated with NAD: NADP ratio (r=-0.676, p=0.022) post SIT, but not pre 
SIT (Table 5).  
 
Principal Component and Partial Least Squares analysis  
 
Principal Component Analysis (PCA) was applied to determine whether there were patterns 
discernible in the dataset that could be linked to the variable anthropometric and metabolic 
responses to SIT. PCA conducted on the entire hSIRTNAD gene expression dataset did not 
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reveal obvious patterns. However, focus on the post SIT gene expression profiles resulted in a 
PCA biplot explaining 44% of the dataset variation (Figure 5A), with clustering of females 
participants, indicating differing responses of the sirtuin/NAD system to SIT compared to 
males and in their sirtuin/NAD system responses to SIT (Figure 5A). Partial Least Squares 
(PLS) analysis indicated associated body composition and metabolic factors distinguishing 
male and female responses to SIT using normalized hSIRTNADplex gene expression (Y) and 
anthropometric and metabolic marker data (X) (Figure 5B).  The PLS plot identified body fat 
levels as a factor associated with clustering of female participants (Figure 5B). Glucose and 
insulin are positioned further from female participants indicating that these factors may also 
differ in male and female participants in response to SIT (Figure 5B).  Notably, NAMPT and 
ABCA1 expression levels are closely associated with glucose and insulin levels (Figure 5B) 
reflecting the identified positive correlation post SIT (Table 5) providing further indication that 
these genes are responsive to glucose and insulin (Figure 4). 
 
Discussion  
 
Supervised SIT has emerged as a strategy to improve exercise performance and health, but as 
with all exercise there is clear inter-individual variation in responses (Ruchat et al. 2010). In 
support of previous reports this study observed improvements in body composition (Figure 1), 
insulin sensitivity and lipid profiles in response to SIT. Interactions with individual genetics 
may be a factor in individual responses to exercise (Ruchat et al. 2010) and transcriptional 
responses of the SIRT/NAD system to SIT were investigated to determine associations with 
the responses to SIT in blood samples.  
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The sirtuin/NAD system consists of 7 sirtuin genes (SIRT1-7) and genes encoding enzymes 
that are involved in de novo synthesis of NAD from dietary tryptophan and vitamin B3. 
Additionally, there are a number of enzymes that are involved in recycling NAD to increase 
and up regulate sirtuin activity in order to maintain homeostasis and respond to various 
stressors (Ying 2008). This study measured blood profiles of the sirtuin/NAD system pre and 
post SIT to determine whether SIT led to a shift in the homeostatic sirtuin/NAD profile in each 
participant as opposed to focusing on acute effects of SIT. Corresponding shifts in other blood 
factors were considered in parallel two days post the final SIT session. Results of 
transcriptional profiling of blood from our volunteers indicated interactions with the sirtuin 
system, with small, but significant down regulation of CD38 (which depletes NAD) and up 
regulation of NMNAT1 and NAMPT (rate limiting enzymes in NAD synthesis) and ABCA1 (a 
lipid transporter that alters blood cholesterol). This evidence was further supported by 
correlations showing co-regulated expression of this small gene set (Table 4). Importantly, it 
is now well recognised that small changes in a gene set within a biochemical pathway are often 
related to biologically meaningful changes (Subramanian et al. 2005). The correlated gene 
expression of NAMPT, NMNAT1, CD38 and ABCA1 post SIT (Table 4) indicates that these 
may be key components of the sirtuin/NAD system responses to exercise training. Indeed, up-
regulation of NAMPT and NMNAT1 may be a key response to increased demand for NAD in 
response to glucose and increased exercise. NAMPT activity elevates synthesis of nicotinamide 
mononucleotide (NMN), the rate limiting step for NMNAT1 conversion of NMN to NAD (for 
review see, Garten et al. 2015). However, reduced levels of plasma vitamin B3 post SIT (seen 
in 13 of the 20 participants) (Figure 4B) may reflect on the increased demand for these rate-
limiting enzymes to recycle NAD precursors. The corresponding down regulation of CD38 in 
response to glucose may be a compensatory factor to alleviate increased demand for NAD in 
regulating the response to elevated plasma glucose. NAMPT was negatively correlated with 
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NAD:NADP ratios. This reduction in NAD:NADP ratios post SIT may be a factor prompting 
the up regulation of NAMPT and also the observed up regulation of NMNAT1. Reduced 
NAD:NADP ratios also imply depletion and or increased demand for NAD. This suggests that 
gaining further positive effects of exercise may be augmented by ensuring dietary sources of 
tryptophan and vitamin B3 are optimal for the individual. NAMPT has also emerged as player 
in glucose regulation (Hajianfar et al. 2012; Revollo et al. 2007). Further analysis was 
conducted to determine whether elevated NAMPT gene expression was associated with 
increased plasma NAMPT since it has been reported that elevated levels of intracellular 
NAMPT may lead to increased secretion of extracellular NAMPT (Yoon et al. 2015). 
Variations in extracellular NAMPT plasma levels were observed in the study participants and 
were not directly correlated with expression of NAMPT in blood. This may be attributed to 
differences in body fat levels in the study participants as studies have indicated that 
extracellular NAMPT may be primarily secreted from adipose tissue rather than blood cells 
(Berndt et al 2005; Yoon et al. 2015).   
 
PCA and PLS plots (Figure 5) indicated that the variation in sirtuin/NAD system responses to 
SIT may be attributed, in part, to sex differences. This is supported by a recent study reporting 
sex differences in response to 12 weeks of sprint interval training (Bagley et al. 2016). 
Additionally, it was noted that individual male participants (IDs 1, 6 and 19) appeared to 
respond differently to SIT in comparison with the remainder of the male cohort (Figure 5). 
Furthermore, these three male participants had distinctly different responses from each other 
with respect to favourable improvements in body composition and metabolic markers post SIT. 
Different responses were associated with body composition, glucose regulation and cholesterol 
levels and sirtuin system gene expression profiles. Previous studies have identified differing 
transcriptional profiles in muscle associated with individuals who demonstrate biological 
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variation in responses to exercise (Keller et al. 2011). Incorporation of measurement of 
corresponding blood and tissue level sirtuin/NAD system transcriptional profiles in the design 
of future studies are desirable. Correlated profiles may provide further insights on individual 
responses to physical activity in tissues that are specifically targeted by training.  
  
The current pilot study was not without limitations. Due to technical issues we were not able 
to record power output during SIT and inter-individual variations in work could contribute to 
some of the differences observed. However, participants were asked to give a maximal effort, 
as the majority of SIT interventions do and rely on. The volunteers were supervised during 
each session and so any major issues with effort are unlikely. The current study did not account 
for hormonal differences at different points in the menstrual cycle and future work should 
consider hormone levels. However, irrespective of potential variation in menstrual status, 
sirtuin/NAD blood gene expression profiles show less variation when compared to males. It 
seems unlikely that menstrual status has a large effect. This study did not use a control group. 
Hence, a comparison with a group not participating in regular SIT sessions was not possible. 
Responses to SIT were thus compared within individuals using pre-SIT intervention 
measurements for comparison with post-SIT measurements. Extending SIT studies may 
facilitate assessments over a period when the study subjects refrain from SIT. It is difficult to 
provide an appropriate comparable control group for SIT. Monitoring of physical activity levels 
in the group not participating in SIT would be an important factor to reduce confounding 
responses during the intervention period. Habitual physical activity levels were not assessed or 
whether these changed during the SIT period. All aspects of physical activity (not only the SIT) 
may alter the sirtuin/NAD system and should be considered in design of future studies.  
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In conclusion, significant improvements in body composition parameters (body mass and body 
fat) were achieved in response to SIT, but associated significant improvements in mean levels 
of metabolic health parameters were not observed (Supplementary File S3). However, it was 
noted that although mean levels of metabolic health parameters did not reveal significant 
changes in response to SIT a number of participants did show improved glucose regulation and 
lipid profiles and associated transcriptional responses in the sirtuin/NAD system. Notably, 
metabolic improvements in response to SIT were achieved in individuals with poor health 
parameters measured pre-SIT. Furthermore, differences in female and male participants 
indicated that sex-specific factors may influence responses to SIT. This pilot study establishes 
criteria for designing future studies to investigate responses to SIT. In addition to male and 
female cohorts to determine sex specific effects, measurement of blood and tissue level 
profiles, the inclusion of a control group not undertaking increased physical activity, gathering 
additional data on lifestyle factors, such as habitual physical activity, will further inform 
interpretation of data analysis. Further investigation of the causes of the marked inter-
individual variation in observed responses to SIT will be critical in formulating optimal public 
health messages for SIT and potentially other forms of exercise. 
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Table 1 NetWISP dietary analysis of macronutrient and niacin intake of participants prior to 
SIT 
 
Macro/micronutrient Mean ± SEM Recommended 
Intake 
Fat (% Total Daily Energy Intake) 33.6 ± 2.3 ≤35 
Protein (% Total Daily Energy Intake) 17.8 ± 0.9 ≤15 
Carbohydrate (% Total Daily Energy Intake) 44.5 ± 2.5 ≥50 
Alcohol (% Total Daily Energy Intake) 4.2 ± 1.5 <5 
Niacin (mg/day) 27.8 ± 3.1 13-17 
 
Note: data are presented as mean ± standard error of the mean (n=14). Macronutrient intakes are  
presented as a percentage of total daily energy intake; Niacin intake is presented in milligrams per day.  
Current recommended daily intakes of macronutrients and niacin are indicated. 
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Table 2 Anthropometric changes pre and post SIT 
 
Variable Pre SIT Post SIT 
Body Mass (kg) 73.6 ± 3.2 72.9 ± 3.1* 
BMI (kg/m2) 23.2 ± 0.6 23.1 ± 0.5 
Waist: hip ratio 0.81 ± 0.02 0.79 ± 0.01 
Body Fat (%) 21.6 ± 1.4 20.2 ± 1.3** 
Note: data are presented as mean ± standard error of the  
mean (n=20). Paired t-tests were used at a significance  
level of p<0.05. * indicates p<0.05; ** indicates p<0.01 
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Table 3 Plasma lipids, glucose and insulin 
Variable Pre SIT Post SIT 
Total Cholesterol (mmol l-1) 3.95 ± 0.157 3.87 ± 0.137 
HDL (mmol l-1) 1.36 ± 0.052 1.37 ± 0.068 
LDL (mmol l-1) 2.19 ± 0.150 2.08 ± 0.134 
Non-HDL (mmol l-1) 2.59 ± 0.179 2.50 ± 0.144 
HDL/LDL Ratio 1.69 ± 0.160 1.63± 0.141 
TRG (mmol l-1) 0.88 ± 0.102 0.93 ± 0.102 
Fasting Glucose (mmol l-1) 4.92 ± 0.114 4.87 ± 0.120 
Fasting Insulin (mU l-1) 5.95 ± 1.16 5.53 ± 0.50 
AUC Glucose (mmol l-1 2h-1) 624 ± 19.03 608 ± 19.42 
AUC Insulin (mU l-1 2h-1) 2717 ± 445.94 2523 ± 360.85 
                      Note: Mean levels were not significant (p<0.05) 
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Table 4 Correlation of sirtuin/NAD system genes and pre and post SIT 
 
Gene Time 
Point 
NAMPT CD38 ABCA1 
Pre SIT Post SIT Pre SIT Post SIT Pre SIT Post SIT 
ABCA1 Pre SIT 0.353 0.55* 0.434 -0.135 
  
Post SIT -0.15 0.696** -0.096 0.615**     
NMNAT1 Pre SIT -0.25 0.34 0.208 0.263 0.212 0.18 
Post SIT -0.35 0.66** 0.173 0.459* 0.245 0.689** 
Note: data are presented as R values. Pearson correlations were used at a significance level of p<0.05. * indicates 
p<0.05; ** indicates p<0.01. 
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Table 5 Correlations between gene expression and metabolic  
markers pre and post SIT  
 
Variable NAMPT ABCA1 
Pre SIT Post SIT Pre SIT Post SIT 
Fasted Glucose 0.426 0.636** 0.360 0.466* 
Glucose AUC 0.191 0.462* 0.360 0.378 
LDL -0.115 -0.497* 0.004 -0.449 
NAD: NADP 0.14 -0.68* 0.11 -0.004 
Note: data are presented as R values. Pearson correlations were used  
at a significance level of p<0.05. * indicates p<0.05; ** indicates  
p<0.01. AUC denotes area under the curve.  
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Figures 
 
 
Figure 1 Changes in individual anthropometric measures in response to SIT [A] body mass, 
[B] % body fat [C] BMI [D] waist: hip ratio (n=20). 
 
Figure 2 Plasma glucose, insulin and insulin sensitivity responses to SIT. [A] Mean ± SEM 
glucose area under the curve (AUC) pre and post SIT. [B] Individual glucose AUC changes 
post SIT. [C] Mean ± SEM insulin AUC pre and post SIT. [D] Individual insulin AUC changes 
post SIT. [E] Mean ± SEM insulin sensitivity pre and post SIT. [F] Individual insulin sensitivity 
changes post SIT. Paired t-tests were used on mean levels (n=20) at a significance level of 
p<0.05.  
 
Figure 3 Transcriptional responses of the SIRT/NAD system to SIT. Mean expression for each 
gene (n=20 + SEM) is shown pre-SIT, pre-SIT post OGTT, post SIT and post SIT post OGTT. 
Gene expression was assessed by hSIRTNADplex assay and normalised to internal reference 
gene UBE2D2. Significant (p < 0.05) differences in gene expression comparing pre-SIT to post 
SIT (a), pre SIT OGGT responses (b), post SIT OGGT responses (c) and pre SIT OGGT to 
post SIT OGTT responses (d) are indicated. 
 
Figure 4 Plasma vitamin B3 and NAD:NADP ratios. [A] Mean ± SEM plasma vitamin B3 pre 
and post SIT (0) and post OGTT (1 and 2 hours) (n=20). [B] Individual plasma vitamin B3 
changes post SIT. [C] Mean ± SEM NAD:NADP ratio pre and post SIT (n=11). [D] Individual 
NAD: NADP ratio changes post SIT. [E] Mean ± SEM plasma NAMPT pre and post SIT (0) 
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and post OGTT (1 and 2 hours) (n=20). [F] Individual plasma NAMPT changes post SIT. 
Paired t-tests were used at a significance level of p<0.05. 
 
Figure 5 Principal component (PCA) and partial least squares (PLS) analyses of UBE2D2 
normalised post SIT hSIRTNADplex gene expression and anthropometric and metabolic 
markers. Female (Δ) and male (▲) participants are indicated. [A] PCA biplot post SIT. The 
PCA biplot permits visualisation of inherent clustering patterns of individuals and associated 
gene expression levels (denoted by ● and gene symbol). The measurements all fall within the 
Hotelling T2 95% confidence limit. [B] PLS analysis coefficients of weights of gene expression 
data (Y) and anthropometric and metabolic markers (X) post SIT. The anthropometric and 
metabolic markers are indicated in grey font. The PLS permits visualisation of associations 
between individuals and anthropometric and metabolic markers. 
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